XENETIC BIOSCIENCES, INC. Other Significant Noncash Transaction, Value of Consideration Given
XENETIC BIOSCIENCES, INC. (XBIO) reported Other Significant Noncash Transaction, Value of Consideration Given of -$40.61 thousand for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2016-11-14
- XENETIC BIOSCIENCES, INC. other significant noncash transaction, value of consideration given for the quarter ending 2016-09-30 was -$40.61K, a 9885.78% decline year-over-year.
- XENETIC BIOSCIENCES, INC. other significant noncash transaction, value of consideration given for the quarter ending 2015-09-30 was $415.00.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 3 month | Other Significant Noncash Transaction, Value of Consideration Given 6 month | Other Significant Noncash Transaction, Value of Consideration Given 9 month |
|---|---|---|---|
| 2016-09-30 | -$40.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$40.61K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-15 | ||
| 2015-09-30 | $415.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $129.74K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $129.33K 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |